Compare OGI & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGI | ORMP |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.0M | 165.3M |
| IPO Year | 2015 | 2010 |
| Metric | OGI | ORMP |
|---|---|---|
| Price | $1.02 | $4.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 554.6K | 470.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $20.10 | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | $13.91 | ★ $5.05 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $0.92 | $1.98 |
| 52 Week High | $2.24 | $5.19 |
| Indicator | OGI | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 60.43 |
| Support Level | $0.92 | $3.69 |
| Resistance Level | $1.21 | $5.10 |
| Average True Range (ATR) | 0.05 | 0.32 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 64.29 | 58.74 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.